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Background: Oxidative stress may lead to an increased level of unrepaired cellular DNA damage, which is
discussed as one risk for tumor initiation. Mismatch repair (MMR) enzymes act as proofreading complexes that
maintain the genomic integrity and MMR-deficient cells show an increased mutation rate. One important gene in
the MMR complex is the MutL homolog 1 (MLH1) gene. Since a diet rich in antioxidants has the potential to
counteract harmful effects by reactive oxygen species (ROS), we investigated the impact of an antioxidant, folate,
and vitamin rich diet on the epigenetic pattern of MLH1. These effects were analyzed in individuals with non-insulin
depended diabetes mellitus type 2 (NIDDM2) and impaired fasting glucose (IFG).
Methods: In this post-hoc analysis of a randomized trial we analyzed DNA methylation of MLH1, MSH2, and MGMT
at baseline and after 8 weeks of intervention, consisting of 300 g vegetables and 25 ml plant oil rich in
polyunsaturated fatty acids per day. DNA methylation was quantified using combined bisulfite restriction enzyme
analysis (COBRA) and pyrosequencing. MLH1 and DNMT1 mRNA expression were investigated by qRT-PCR. DNA
damage was assessed by COMET assay. Student’s two-tailed paired t test and one-way ANOVA with Scheffé
corrected Post hoc test was used to determine significant methylation and expression differences. Two-tailed
Pearson test was used to determine correlations between methylation level, gene expression, and DNA strand
break amount.
Results: The intervention resulted in significantly higher CpG methylation in two particular MLH1 promoter regions
and the MGMT promoter. DNA strand breaks and methylation levels correlated significantly. The expression of
MLH1, DNMT1, and the promoter methylation of MSH2 remained stable. CpG methylation levels and gene
expression did not correlate.
Conclusion: This vitamin and antioxidant rich diet affected the CpG methylation of MLH1. The higher methylation
might be a result of the ROS scavenging antioxidant rich diet, leading to lower activity of DNA demethylating
enzymes. Our results suggest the hypothesis of CpG demethylation via DNA repair enzymes under these
circumstances. NIDDM2 and IFG patients benefit from this simple dietary intervention involving epigenetic and
DNA repair mechanisms.
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Table 1 Characteristics of the study population
NIDDM2 IFG LC
Number 10 5 8
Women 4 3 5
Age, years 66.30 ± 5.89 69.0 ± 2.35 26.50 ± 1.77
BMI, kg/m2 33.8 ± 6.46 27.7 ± 4.14 21.2 ± 1.55
Results for age and BMI presented as mean ± SD. Number, number of
participants; BMI, body mass index; NIDDM2, patients with non-insuline-
dependent diabetes mellitus type 2; IFG, patients with impaired fasting
glucose; LC, lean control group.
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Diabetes mellitus type 2 (T2DM) is a multifactorial dis-
ease characterized by hyperlipidemia, visceral obesity,
hypercoagulability, microalbuminuria and hypertension
based on genetic predisposition and environmental fac-
tors resulting in insulin resistance and hyperglycemia.
Diabetic patients have often been described as being
under enhanced oxidative stress [1,2]. Long-term dietary
patterns and status have a large impact on the risk
developing non-communicable diseases like T2DM.
Chronic exposure to elevated amounts in particular of
free fatty acids and palmitate (C16 saturated fatty acid)
leads to a higher reactive oxygen species (ROS) burden,
while long chain polyunsaturated fatty acids such as doc-
osahexaenoic acid (DHA) has the opposite effect [3,4].
The phenotype of chronic hyperglycemia leads to
increased production of ROS also originating from the
substrate overwhelmed electron transport system in the
mitochondria and the plasma membrane nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase [5].
Further, the NADPH oxidase-dependent ROS produc-
tion is directly proportional to accumulated body fat,
although the mechanisms behind this are still not en-
tirely clear [6,7].
In healthy cells, ROS does not implicate harmful
effects per se; when consistently regulated, ROS has an
intracellular signaling role [8]. This vital balance can be
disrupted by an excess of ROS and/or lack of antioxi-
dants (AO) leading to cytotoxic and genotoxic oxidative
stress, resulting in DNA strand breaks [8]. The ROS-
induced spontaneous deamination of cytosine to uracil
(unmethylated cytosine) and 5-hydroxyuracil (methy-
lated cytosine) results in a G:C to A:T transition muta-
tion, since they both preferentially pair with adenosine
during DNA replication [9]. Likewise, guanine can be
oxidized to 8-oxo-7,8 dihydroguanine (8-oxoG) and
leads to a G:C to T:A transition mutation, due to its mis-
pairing with adenosine [9].
In order to ensure DNA integrity, especially in diabetic
patients, DNA repair enzymes are crucial. The mismatch
repair (MMR) enzyme complex (MLH1 and MSH2 ap-
pear to play a key role) acts as a proofreading system dur-
ing DNA synthesis and repairs 8-oxoG lesions [10,11].
MGMT removes alkyl adducts from the DNA especially
O6-methylguanine, which is read as an adenine by the
DNA polymerase. Evidence shows that AO are able to in-
crease DNA repair enzyme activities [12,13]. MLH1 and
MGMT promoter are inactivated by hypermethylation,
and a promoter methylation-dependent downregulation
of the corresponding gene expression in some cancer tis-
sues has been found [14].
Environmental factors have a significant impact upon
the epigenetic program of gene expression. Dietary fac-
tors have been found to alter DNA methylation bothglobally, and locus-specifically, leading to a changed ex-
pression of genes [15-17]. These modifications can be
epigenetically inherited through DNA methylation to the
next generation [18].
Numerous epidemiological studies have shown that nu-
tritional folate, by providing one-carbon units, and AO
play an important role for both DNA methylation and nu-
cleotide biosynthesis reactions [19,20], and as a conse-
quence, for DNA repair. Folic acid deficiency causes
epigenetic changes by diminishing remethylation of s-
adenosyl-homocysteine (SAH) to s-adenosylmethionine
(SAM) in the methionine cycle, which causes cytosine
demethylation, global DNA hypomethylation, and chromo-
somal instability [21]. In addition, inadequate dietary folate
increases uracil misincorporation, rate of DNA strand
breaks, and chromosome breaks. Furthermore, folic acid
deficiency affects DNA repair by the inhibition of thymi-
dine and purine biosynthesis [21].
Therefore, our primary aim was to assess the impact
of the antioxidant- and vitamin-rich diet on the epigen-
etic pattern of MLH1 in non-insulin-dependent T2DM
(NIDDM2) and patients with impaired fasting glucose
(IFG). In this study, we show that a changed diet rich in
AO and vitamins (especially folate) has the ability to
alter DNA methylation, and compensate ROS-induced
epigenetic lesions.
Study design
This is a post-hoc analysis of a subgroup (n = 15) of a
randomized trial (DIAPLANT) conducted at the Depart-
ment of Nutritional Sciences at the University of Vienna
between January and June 2010. We analyzed the DNA
methylation of MLH1, MGMT, and MSH2 at baseline
and after the 8 weeks ongoing intervention in patients
with NIDDM2 and IFG (Table 1). To assess the natural
and methodological variability of DNA methylation a
lean control group (LC) consisting of 8 volunteer,
healthy adults, who did not receive the intervention was
analyzed separately.
Briefly, the aim of the DIAPLANT study was to inves-
tigate the positive effects of a dietary intervention with
300 g vegetables and 25 ml walnut oil per day, compris-
ing approximately 73% polyunsaturated fatty acids
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for 8 weeks, on the risk factors for late diabetic compli-
cations in T2DM subjects. The focus was on antioxidant
and vitamins (especially folate), and rich green vegeta-
bles (broccoli, zucchini, brussels sprouts, green beans,
cabbage turnip, maize, carrots, peas, cauliflower, soya
beans, cos lettuce and spinach).
Subjects were recruited from a local diabetic clinic
(Diabetes outpatient Clinic, Health Centre South, Vi-
enna, Austria) during their annual health assessment.
All subjects receiving the intervention had to have
stable metabolic control (constant medication regard-
ing glucose, lipid and uric acid metabolism), glycated
hemoglobin (HbA1c) concentration < 9.5%, serum total
cholesterol (TC) < 300 mg/dl (< 7.76 mmol/l), serum tri-
glycerides (TG) < 500 mg/dl (< 5.7 mmol/l) and serum
creatinine< 2.5 mg/dl (< 221 μmol/l). Only subjects
with stable body weight, constant dietary habits and
physical activity levels for at least four weeks before entry
to the study were included. Subjects who intended to
change dietary habits, frequency of physical activity or
body weight within the study period were not allowed to
participate. Exclusion criteria also included smoking, in-
take of fish oil capsules and other fatty acids. All medical
therapies of subjects were continued unchanged through-
out the study. Results of the DIAPLANT study will be
reported elsewhere. The study protocol was approved by
the Ethical Committee of the City of Vienna (EK09-218-
VK_NZ). All participants gave their written consent.Results
Oral folate intake
The calculated mean ± SD of folate contained in the
intervention vegetables was 153.00 μg ± 82.32 μg per
300 g. Oral folate intake, assessed by 24-h recalls, was
significantly increased after the intervention compared
to baseline values (127.66 μg ± 195.27, P= 0.024).Figure 1 MLH1 Region 1 sequence and primers. MLH1 region 1: Bisulfit
pyrosequencing. Analyzed CpGs within the sequenced area are shaded oraAnalysis of MLH1 methylation
The BstUI restriction site (CGCG) in the MLH1 pro-
moter analyzed by combined bisulfite restriction ana-
lysis (COBRA) was hypomethylated at all time points
and possible minor methylation shifts were not detect-
able (see Additional file 1) [22]. DNA methylation dif-
ferences between baseline (T0) and after 8 weeks of
the intervention (T1) were not significantly different in
the intervention groups.
Pyrosequencing of the MLH1 region1 (MLH1-1)
Quantitative analysis of the investigated area (65 bp,
Figure 1 and Figure 2) on the forward strand showed
significant changes over time at CpG sites numbers 1, 4
and 6 (Table 2). Site number 2 was not analyzed due to
the long 5-nucleotide homopolymer T stretch (Figure 3),
which has also been observed to cause problems in ana-
lysis, as in other studies [23]. The mean methylation over
the seven CpGs was significantly (P=0.001) elevated after
the intervention (Figures 4 and 5). This area includes a se-
quence motif previously analyzed by COBRA [24] at
CpG numbers 6 and 7 that has not yet been analyzed
by pyrosequencing.
Pyrosequencing of the MLH1 region2 (MLH1-2)
This region covers a part of the reverse strand of the
MLH1-1 region (see Figures 2 and 6.). The mean methy-
lation was significantly higher (0.564%± 0.696, P= 0.007)
after the intervention in both NIDDM2 and IFG subjects
(Figure 4).
Pyrosequencing of the MLH1 region 3 (MLH1-3)
This region is situated 300 bp upstream of the other two
MLH1 pyrosequenced regions (see Figure 2.). The
methylation levels were very low (0% to 2%) and
remained stable over time (Figure 4). No group-specific
pattern could be found.e-converted MLH1 promoter 50-30sequence and primers used for
nge.
Figure 2 Analyzed regions within the MLH1 promoter. CpG methylation assay overview within the MLH1 promoter region 50- 30.
Approximately 730 to 240 bp upstream of the translational start site, 25 CpG sites were analyzed on forward and/or reverse strand.
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The MGMT mean promoter (see Additional file 2)
methylation was significantly higher (0.337%± 0.468,
P= 0.023) after the intervention (Figure 4 and Table 3).
The percentages of methylated cytosine were generally
low (≤ 5%). No correlation of CpG methylation with the
MLH1 expression could be found. DNA methylation dif-
ferences between baseline and T1 were not significantly
different in the intervention groups. Patient number 76
(IFG) showed a baseline methylation level of 11% and 2%
after intervention at CpG number 8, leading to a dis-
torted statistic at this position. Excluding patient 76 from
pooled statistics leads to + 0.733% overall methylation
(SE = 0.146, P < 0.001). A European Molecular Biology
Open Software Suite (EMBOSS) transcription factor pre-
diction within shared motifs (> 5 bp; 50-AGCCCG-30 and
50-GGACAGC-30) with MLH1 region 1 was negative.
Quantitative analysis of MSH2 promoter (see Additional
file 3) methylation did not reveal any aberrant methylation
in the investigated samples. The percentages of methy-
lated cytosine were generally low (≤ 5%). The methylation
level remained stable over time. Neither a group-specific
pattern nor a correlation of CpG methylation with the
MLH1 expression could be found.Table 2 MLH1 region 1 group-specific methylation levels for
paired t-test of methylation changes from baseline to eight w
Health group CpG 1 CpG 3 CpG 4
NIDDM2 0,666* 0,195 0,810*
SE 0,250 0,429 0,295
P 0,026 0,661 0,023
IFG 1,250 0,919 1,202
SE 0,502 0,502 0,740
P 0,068 0,141 0,180
LC −0,138 −0,060 −0,165
SE 0,180 0,322 0,190
P 0,487 0,861 0,433
CpG numbers 1, 4, 6, and the mean methylation were significantly higher methylat
methylation. Methylation level remained stable in the LC group. Asterisks indicate s
mellitus type 2; IFG, patients with impaired fasting glucose; LC, lean control group;MLH1 and DNMT1 m-RNA expression
Changes in MLH1 and DNMT1 gene expression in re-
sponse to the intervention were quantified by quantita-
tive real-time reverse-transcriptase (qRT)-PCR. Melting
curve analysis showed specific product peaks at 87.26°C,
89.34°C, and 83.67°C for GAPDH, DNMT1, and MLH1,
respectively. Neither a significant expression shift be-
tween the two time points, nor a correlation with methy-
lation levels of CpGs or DNA damage could be found.
MLH1 and DNMT1 expressions were not affected by the
intervention (P= 0.306 and P= 0.932, respectively).
DNA damage
Baseline levels of DNA strand breaks were comparable
between the intervention groups. After the intervention
(T1), more DNA strand breaks were measured in the
IFG group by the H2O2-induced oxidative DNA damage
test (P= 0.006) compared to the NIDDM2 group. We
found significant correlations between the occurrence of
DNA strand breaks and the methylation level of CpG
number 1 (P < 0.01; r=−0.471; see Figure 7), number 3
(P < 0.05; r=−0.370), and number 4 (P < 0.01; r=−0.486)
as well as the mean methylation (P= 0.05; r=−0.361)
within the MLH1-1 assay in the NIDDM2 and IFGeach CpG, mean methylation over the seven CpGs, and
eeks
CpG 5 CpG 6 CpG 7 CpG 8 Mean
−0,025 1,759* 0,032 1,660 0,728*
0,388 0,539 0,320 1,086 0,254
0,950 0,010 0,924 0,161 0,019
0,466 0,547 2,028 1,372 1,112*
0,424 0,786 1,828 0,898 0,278
0,333 0,525 0,330 0,201 0,016
0,173 0,498 −0,064 0,401 0,092
0,251 0,227 0,186 0,285 0,184
0,529 0,093 0,748 0,232 0,642
ed in the IDDM2 group. The IFG group had significantly higher overall
ignificances at P< 0.05. NIDDM2, patients with non-insulin-dependent diabetes
SE, standard error of the mean.
Figure 3 MLH1 region 1 pyrogram. MLH1-1 assay showing seven analyzed sites (sample P44 T0). CpG number 2 was not considered for
analysis. Three bisulfite treatment controls (16, 24, 38) confirm the complete conversion of unmethylated (non-CpG motif) cytosine residues.
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files 4 and 5).
Discussion
While several studies have found that higher ROS levels
induce aberrant DNA hypomethylation [25,26], this
study is among the first to report that a changed diet
can reverse this effect. Our DNA methylation and gene
expression studies reveal a link between specific MLH1
promoter CpG methylations and an optimized diet in
IFG and NIDDM2 patients, but no group-specific DNA
methylation differences between baseline and T1 could
be found. A novel finding is the identification of three
variable CpG methylation positions situated in the
MLH1 promoter, which to our knowledge has not been
published before. Due to the AO- and folate-rich dietary
intervention, the methylation levels of these CpGs were
higher compared to the baseline. Our analysis was not
intended to show differences in methylation variabilityFigure 4 Mean DNA methylation levels. Mean DNA methylation levels in
type 2 (NIDDM2) and impaired fasting glucose (IFG) groups were pooled a
methylation differences between baseline and T1 were found. P-values arebetween NIDDM2/IFG patients and lean control sub-
jects. Nevertheless, there is clear evidence of a negative
correlation between methylation levels and age in our
study population.
Chang et al. demonstrated that non-cytotoxic levels of
H2O2 significantly reduced the activity of the MMR system
in repairing single-base and insertion/deletion loop mis-
matches in a dose-dependent manner. The different MMR
activity was not a result of altered expression levels, but
based on posttranslational enzyme degradations by H2O2.
They further propose that ROS-induced stress reduces
MMR function and may play a role in the low frequency of
microsatellite instability (MSI) detected in inflamed tissues
[27]. Therefore, our gene expression data may not reflect
MMR activity. Nevertheless, we showed that the variable
MLH1 promoter methylation levels are not affecting its ex-
pression, hence not affecting MMR activity.
The detected MLH1 methylation levels were consist-
ently low (0% to 12%), independently from the timethe intervention groups. Non-insulin-dependent diabetes mellitus
s they showed almost the same picture and no group-specific DNA
based on the paired t-test.
Figure 5 MLH1 region 1 mean DNA methylation levels. Detail of
MLH1 region 1. Mean DNA methylation levels over seven CpGs in
the intervention groups, non-insulin-dependent diabetes mellitus
type 2 (NIDDM2) and impaired fasting glucose (IFG), and the lean
control group (LC). P-values are based on the paired t-test.
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pression of MLH1 was not affected by the methylation
levels. This suggests that the expression is not regulated
by the methylation levels of the analyzed sites in non-
cancer patients. Consistent with other findings [29,30],
increases in methylation are not explained by higher
DNMT1 expressions. Although the oral intake of folate
had increased significantly after the intervention, it had
no effect on the DNMT1 expression. This may indicate
that no folate- or methyldonor-deficiency was present
before the intervention [31].
Possible histone modification involved in the regulation
of MLH1 expression and its effect on DNA methylation
[32-34] do not offer explanations for our results. HistoneFigure 6 MLH1 region 2 pyrogram. The extended MLH1-2 assay pyrogramodifications such as H3K9me3, H3K27me2, and
H3K27me3, apparently do not directly affect MLH1 ex-
pression but may serve to index the promoter region for
additional epigenetic control [35]. We cannot rule out the
involvement of histone modifications leading to higher
methylation levels, but in stark contrast we hypothesize
that the intervention did not directly induce higher methy-
lation levels, but suppresses the evident loss of methyla-
tion before the intervention. CpG-relevant ROS-induced
DNA damages are 8-oxoguanine and the conversion
of 5-methyl-cytosine (5mC) to 5-hydroxymethylcytosine
(5hmC) and 5-hydroxymethyluracil (5hmU), predomin-
antly repaired through the MMR, base excision repair
(BER), and nucleotide excision repair (NER) pathway, re-
spectively [36,37]. So far it remains unclear how exactly
CpG methylation marks are removed from the DNA,
even though active mechanisms have been discussed [38].
Evidence is provided for both direct and indirect demethy-
lation [39,40]. Barreto et al. propose that active and direct
DNA demethylation is accomplished through a GADD45-
dependent process of DNA repair (NER and BER) that
involves nucleotide exchange, replacing 5-methyl-cytosine
with unmodified cytosine, and it is possible that this is the
physiological mechanism that operates typically in vivo.
In vitro, GADD45 knockdown resulted in similar methy-
lation differences to our results (see Barreto et al.
Figure 3c-d) [39]. Different enzymes (for example TET,
AID/APOBEC) have been found to modify the methylated
cytosine (by hydroxylation, deamination, oxidation, or a
combination of these modifications), leading to its replace-
ment by DNA repair. They act indirectly to mediate DNA
demethylation. TET1, 2, and 3 catalyze the conversion of
5mC to 5hmC, which is then replaced with an unmethy-
lated cytosine by the BER enzymes via DNA repair [41].
Conclusions
Based on these findings we propose that the low initial
methylation levels on MLH1 and MGMT are the result
of increased oxidative stress, which causes DNA lesions
resulting in increased DNA repair activity. The latterm showing 13 analyzed sites (sample P27 T0).
Table 3 MGMT group-specific methylation levels for each CpG and the mean methylation over the ten CpGs
Health group CpG 1 CpG 2 CpG 3 CpG 4 CpG 5 CpG 6 CpG 7 CpG 8 CpG 9 CpG 10 Mean
NIDDM2 0,224 0,565 0,272 0,232 0,413 0,436 0,106 0,373* 0,103 0,853 0,420
SE 0,163 0,270 0,127 0,165 0,191 0,173 0,139 0,155 0,142 0,426 0,192
P 0,210 0,075 0,070 0,202 0,067 0,039 0,468 0,047 0,492 0,086 0,065
IFG 0,226 0,386 0,086 0,183 0,493 0,422 0,129 −1,599 0,168 0,856 0,204
SE 0,143 0,310 0,088 0,125 0,224 0,214 0,158 1,840 0,255 0,310 0,146
P 0,188 0,281 0,384 0,218 0,092 0,120 0,461 0,434 0,546 0,051 0,233
pooled 0,225 0,496* 0,200* 0,213 0,443* 0,431* 0,115 −0,386 0,128 0,854* 0,337*
SE 0,110 0,198 0,087 0,109 0,140 0,129 0,101 0,721 0,125 0,279 0,130
P 0,063 0,027 0,039 0,073 0,008 0,006 0,275 0,602 0,327 0,010 0,023
Paired t-test of methylation changes between baseline (T0) and 8 weeks (T1). CpG numbers 2, 3, 5, 6, and 10 and the mean methylation were significantly higher
methylated in the intervention groups (pooled). Asterisks indicate significances at P< 0.05. NIDDM2, patients with non-insulin-dependent diabetes mellitus type 2;
IFG, patients with impaired fasting glucose; LC, lean control group; SE, standard error of the mean.
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direct demethylation. The nutritional intervention might
have led to a lower ROS burden and diminished the
demethylating effects, resulting in higher overall methy-
lation levels, and helped to maintain crucial and tissue-
specific methylation marks with possible regulatory
function. This finding need to be further investigated to
reveal the exact underlying mechanisms behind the
ROS-induced demethylation in relation to MSI and
cancer-relevant promoter demethylation of oncogene,
leading to initiation of tumors.Figure 7 Correlation between DNA strand breaks and CpG
number 4 methylation. Significant correlation over all time points
between the occurrence of DNA strand breaks and the DNA
methylation level at CpG number 4 within the MLH1 region 1
(P< 0.01; r=−0.486).Methods
Sample collection
Blood was sampled before (T0) and after 8 weeks of diet-
ary intervention (T1) using PAXgene Blood DNA tubes
and the PAXgene Blood RNA tubes (Qiagen, Hilden,
Germany). The samples were stored until analyses at
−20°C.Folate quantification
On the day before blood sampling, 24-h recalls of food
intake were obtained from the subjects. The dietary
composition of the vegetables and 24-h recalls were
evaluated using the nutritional software NUT.S (BLS
II.3.1., Karlsruhe, Germany).DNA isolation and bisulfite conversion
DNA was extracted using the PAXgene Blood DNA Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. For methylation analysis, all samples
were bisulfite-converted with the EpiTectBisulfite Kit
(Qiagen, Hilden, Germany), resulting in the deamination
of unmethylated cytosine to uracil, whereas methylated
cytosine remain unchanged. The EpiTect Whole Bisulfi-
tome Kit (Qiagen, Hilden, Germany) was used to amplify
2 μl converted DNA. The concentration of DNA was
measured on a Pico100 (Picodrop Limited, Hinxton,
UK). All reactions were carried out according to manu-
facturer’s protocols. Samples were stored at −20°C.RNA isolation and reverse transcription
Total RNA was extracted from blood samples using the
PAXgene Blood RNA Kit (Qiagen, Hilden, Germany) fol-
lowing the producer’s handbook. The random primers
(hexamers) of the Phusion RT-PCR Kit (Finnzymes, Van-
taa, Finland) were used to reverse-transcribe 5 μl of total
RNA into single-stranded DNA. The concentration of
Table 4 Primers used for PCR methods
Primer name Sequence 50-30 Application Size Number of CpGs Ref
MLH1-C-FW GTATTTTTGTTTTTATTGGTTGGATA COBRA 294 bp 1 [24]
MLH1-C-RE AATACCTTCAACCAATCACCTCAATA COBRA
MLH1-1-FW GGAGAGGAGGAGTTTGAGAAG PSQ 269 bp 7
MLH1-1-RE Biotin-AATACCAATCAAATTTCTCAACTCTAT PSQ
MLH1-1-Seq TTGTTTTTATTGGTTGGATAT PSQ
MGMT-FW Biotin-GGATATGTTGGGATAGTT PSQ 266 bp 5 [42]
MGMT-RE AAACTAAACAACACCTAAA PSQ
MGMT-Seq CCCAAACACTCACCAAA PSQ
MLH1-Q-FW TTCTCAGGTTATCGGAGCCAGCAC qRT-PCR 288 bp [43]
MLH1-Q-RE CTTCGTCCCAATTCACCTCAGTGG qRT-PCR
DNMT1-Q-FW ACCGCTTCTACTTCCTCGAGGCCTA qRT-PCR 335 bp [44]
DNMT1-Q-RE GTTGCAGTCCTCTGTGAACACTGTGG qRT-PCR
GAPDH-Q-FW CGACCACTTTGTCAAGCTCA qRT-PCR 205 bp [45]
GAPDH-Q-RE AGGGGTCTACATGGCAACTG qRT-PCR
COBRA, combined bisulfite restriction analysis: PSQ, pyrosequencing: qRT-PCR, quantitative real-time reverse-transcriptase polymerase chain reaction; Ref,
reference.
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Hinxton, UK). The samples were stored at −20°C.
PCR and restriction enzymatic digestion - COBRA
All bisulfite-treated samples were investigated by PCR
and endonuclease digestion. The primers of Deng et al.
were used for PCR [24]. The two methylation-specific
primers MLH1-C-FW and MLH1-C-RE (Table 4) were
chosen for the touchdown PCR amplification. The PCR
was always carried out in 50 μl reaction mixtures; these
contained 25 μl 2× SensiMix Probe polymerase master-
mix (Bioline, London, UK), 625 nM of each primer, and
20 ng bisulfite-converted DNA. PCR conditions were
95°C for 10 minutes, 15 cycles of 95°C for 10 s, 55°C to
51°C for 1 minute, -0.2°C per cycle, 72°C for 1 minute
followed by 25 cycles of 95°C for 40 s, 51°C for 40 s,
72°C for 40 s and a final elongation at 72°C for 10 min-
utes. After amplification, the PCR products were purified
by isopropanol-precipitation. For enzymatic digestion,
10 μl PCR product was digested with 1U of BstUI (New
England Biolabs, Frankfurt am Main, Germany) and NEB4
Buffer in 25 μl total volume at 60°C for 3 h. The digested
fragments were separated by 2% agarose gel electrophor-
esis. Both CpG sites within the BstUI need to be methy-
lated to be digested by BstUI. If the recognition site
(CGCG) is methylated, its ssPCR product (294 bp) is
digested into a 206 bp and an 88 bp fragment. If the
CGCG motif is not methylated, the amplicon is not
digested. The digested DNA was separated on 3.5% agar-
ose gels in 1× tris-acetate ethylenediaminetetraacetic acid
(TAE) and stained with GelRed (Biotium, Hayward, CA).
Bands were analyzed using ImageJ 1.44p and quantified
relative to the synthetic fully methylated /unmethylatedcontrol-DNA (Qiagen, Hilden, Germany). The proportion
of methylated versus unmethylated DNA was deter-
mined from the relative intensities of cut and uncut
PCR product.
Quantitative promoter methylation analyses by DNA
pyrosequencing
We performed quantitative methylation analyses of the
MLH1, MGMT, and MSH2 promoter by pyrosequencing
of sodium bisulfite-modified DNA using the PyroMark
Q24 (Qiagen, Hilden, Germany). DNA methylation was
determined in three different regions inside the MLH1
promoter (Figure 2). PCR were performed in 25 μl reac-
tion mixtures with 12.5 μl PyroMark 2× PCR master
mix, 280 nM of each primer (Table 4), 2.5 ml CoralLoad
Concentrate 10× (Qiagen, Hilden, Germany), and 25 ng
bisulfite converted DNA for MGMT and 25 ng of Epi-
Tect Whole Bisulfitome (Qiagen, Hilden, Germany)-
amplified DNA for all other analyses. PCR conditions
were 95°C for 15 minutes; 45 cycles of 94°C for 30 s, a.)
for MGMT 47.5°C for 45 s, b.), for all other genes, 56°C
for 30 s; 72°C for 30 s, and a final elongation at 72°C for
10 minutes. One of the PCR primers was biotinylated to
purify the final PCR product using streptavidin-coated
SepharoseW beads (GE Healthcare, Vienna, Austria).
Additionally three PyroMark CpG assay kits (Qiagen,
Hilden, Germany) were used following the manufac-
turer’s instructions (Table 5). The MLH1-2 assay was
manually extended to analyze thirteen CpGs instead of
six. PCR products were checked by 3.5% agarose gel
electrophoresis. A total of 12.5 μl of the PCR product
was used for subsequent pyrosequencing using a Pyro-
Mark Q24 System (Qiagen, Hilden, Germany). Briefly,
Table 5 PyroMark CpG assay kits (Qiagen, Hilden, Germany)
Assay name GeneGlobe Catalogue number Size Sequence to analyze 50-30 Number of CpGs
MLH1-2 PM00104860 203 bp YGAATATTAYGAGYGGTATGTGGYGGAYGGYGA 6 (13)*
MLH1-3 PM00104839 246 bp GYGTTTGYGYGTTAGAGATYGTTGTTYGT 5
MSH2 PM00007777 190 bp YGYGTTTGYGGGTTTTYGYGYGATTTAGGYGT 7
* provided kit was manually extended to analyze 13 instead of 6 CpGs.
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product were washed and denatured using 0.2 M NaOH
solution and rewashed using the pyrosequencing Vac-
uum Prep Tool (Qiagen, Hilden, Germany). The purified
single-stranded PCR product was released to the anneal-
ing buffer (Qiagen, Hilden, Germany) containing the
corresponding pyrosequencing primer (300 nM). Subse-
quent quantification of CpG methylation levels was per-
formed using the PyroMark Q24 software (Qiagen,
Hilden, Germany). Each pyrosequencing assay was per-
formed on duplicates. For quality control, each experi-
ment included non-CpG cytosines as internal controls
to verify efficient sodium bisulfite DNA conversion. We
also included synthetic fully methylated /unmethylated
control-DNA (Qiagen, Hilden, Germany).
qRT-PCR
The mRNA level of MLH1, DNMT1, and GAPDH as an
endogenous control gene for normalization was analyzed
in triplicates on a StepOne Plus real-time PCR system
(Applied Biosystems, Vienna, Austria) using the SYBR
Green approach. Each reaction mix consisted of 5 μl
SensiFAST SYBRgreen (Bioline GmbH, London, UK),
300nM primers (Table 4), and 100 ng cDNA to a total
volume of 10 μl. PCR conditions were 95°C for 2 min-
utes, 40 cycles of 95°C for 30 s, 60°C for 10 s, and 72°C
for 5 s, followed by a melt curve analysis. The efficiency
for DNMT1, MLH1, and GAPDH, was 103.5%, 106.7%,
and 109.4%, respectively. Calculations were performed
using the comparative Ct method.
Comet assay
A Comet assay was performed based on the protocol
published by Azqueta [46]. For the evaluation of DNA
damage, Komet 5.5 image analysis software (Kinetic Im-
aging Limited, Nottingham, UK) was used, which was
linked to a fluorescent microscope. For every sample
two gels with 50 cells each were randomly scored. The
percentage of DNA in the tail (% tail DNA) was deter-
mined and the mean was calculated.
Statistical analyses
Methylation levels and expression data of 23 paired sam-
ples were analyzed with SPSS 20 (IBM, Armonk, NY).
The Kolmogorov-Smirnov test was used to test for nor-
mality of the distributions. The Student’s two-tailedpaired t-test and one-way analysis of variance (ANOVA)
with the Scheffé post hoc correction test were used to
determine significant differences. The two-tailed Pearson
test was used to determine correlations between methy-
lation level, gene expression, and amount of DNA strand
break. All statistics were tested for possible associations
with age and sex; no significant associations were found.
A P-value < 0.05 was considered statistically significant.
All data shown are mean± SD unless otherwise
indicated.Additional files
Additional file 1: Figure S1. COBRA gelelectorphoresis. Figure showing
gelelectorphoresis of combined bisufite restriction analysis (COBRA)
before (10 μl) and after (10 μl and 15 μl) BSTUI digestion. 100 bp DNA
ladder.
Additional file 2: Figure S2. MGMT pyrosequencing location. Figure
showing methylation assay overview within the MGMT promoter region
50- 30. Ten CpG sites were analyzed by reverse-sequencing the upper
strand. CpG island concentration is shown in the lower green.
Additional file 3: Figure S3. MSH2 pyrosequencing location. Figure
showing methylation assay overview within the MSH2 promoter region
50- 30. Approximately 260 to 230 bp upstream of the translational start
site, seven CpG sites were analyzed on the forward strand. CpG island
concentration is shown in the lower green.
Additional file 4: Figure S4. Correlation between DNA strand breaks
and CpG number 1 methylation. Figure showing significant correlation
over all time points between the occurrence of DNA strand breaks and
the DNA methylation level at CpG number 1 within the MLH1 region
1 (P <0.01; r = −0.471).
Additional file 5: Figure S5. Correlation between DNA strand breaks
and mean methylation. Figure showing correlation over all time points
between the occurrence of DNA strand breaks and the mean DNA
methylation level of the MLH1 region 1 (P= 0.05; r=−0.361).Abbreviations
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